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Cervical cancer is the second most common life-threatening cancer
amongwomenworldwide, with 470,000 new cases and nearly 233,000
deaths per year [1]. Human papilloma virus (HPV) infection, especially
HPV-16 andHPV-18, plays amajor role in the etiology of cervical cancer
[2,3] and [4], but HPV alone is not sufﬁcient to induce cancer. The
increasing emphasis of microRNAs in cancer development and
progression makes it imperative to search for variations in miRNAs
and their target binding sites whichwould be critical in maintenance of
cellular differentiation, apoptosis and proliferation in cervical cancer.
MicroRNAs are endogenous non-coding RNAs of 22 nucleotides in
length, regulating genes in organisms by pairing to the 3′ un-translated
regions (UTRs) of messenger RNAs (mRNAs) of target genes and
specifyingmRNA cleavage or repression of protein synthesis [5] and [6].
MicroRNA genes represent only a small part of the genome, but they
regulate approximately 20–30% of all human genes and there is an
average of 200 predicted targets per miRNA [6]. Recently, new
mechanisms governing the expression of genes related to cancer
developmenthavebeen identiﬁed.Among them, theposttranscriptional
regulation throughmicroRNAs (miRNAs) ismost interesting and criticalin maintenance of homeostasis. We had recently suggested that the
variations inmiRNAexpression in cervical cancer tissuesmay contribute
to deregulation of the cell cycle regulatory pathway in cervical cancer
[7]. This activation, in turn, leads to repression of other target genes.
ThusmiRNA expression patternsmay serve as potential markers of pre-
invasive cervical disease [8] and [9]. The complex miRNA–RNA induced
silencing complex can inhibit the translation when it binds the 3′ UTR-
mRNA targets with defective complementarity.
Given the important role of miRNA in gene regulation and in
carcinogenesis, we hypothesized that polymorphisms in 3′ UTRs
targeted by miRNAs may alter strength of miRNA binding, with
consequences on regulation of target genes thereby affecting the
individual's cancer risk. In this study we concentrated on Single
nucleotide polymorphisms (SNPs), the most abundant form of DNA
variation in the human genome that contributes to human phenotypic
differences [10]. It is increasingly recognized that regulatory mutations
could make a signiﬁcant contribution to genetic variation, especially for
complex traits, including disease susceptibility. Therefore, the SNPs in
miRNAs or their target sites could potentially alter various biological
processes by inﬂuencing the thermodynamics of the RNA–RNA in-
teractions between miRNAs and their target sites, which may result in
the dysregulation of target genes and subsequently cause phenotype
variation or disease susceptibility. Indeed, recently, upon analyzing the
SNPs in human miRNAs or target sites, several studies have reported a
lower SNP density in these regions when comparing themwith control
regions [11–13] and [14]. However, all these studieswere performed by
analyzing all human miRNAs or target sites together, which may mask
some special features of speciﬁc miRNAs or target sites [15]. Up to this
Fig. 1. (a) Human Bcl-2 putative target of miR-195. Shown is a sequence alignment of
miR-195 and its conserved target site in Bcl-2 3′ UTR, which was downloaded from
TargetScan. The variant BCL2_ 4987856 affects the miRNA-binding site of miR-195 and
the difference of the free energies between the two alleles. (b) Shows the initial energy
(c) Shows the energy after allelic change from RNAhybrid 2.2.
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miRNAs or target sites. Due to the stringent recognition requirement
between themiRNA seed region and its target, a naturally occurring SNP
may have signiﬁcant functional implications for microRNA binding and
posttranscriptional regulation.
In the present work we investigated SNPs in miRNA target sites of
cancer relevant genes and its impact on risk for cervical cancer.We ﬁrst
conducted a bioinformatics genome-wide survey on genes assumed to
be involved cervical cancer and their dysregulated miRNAs. We then
looked for polymorphisms in their target mRNA. We searched for SNPs
residing in the 3′ UTRs of the candidate genes that would potentially
affect novel target sites in humans and assessed their binding impact
computationally. In order to verify this hypothesis, we genotyped the
resulting putatively functional polymorphisms in Indian cervical cancer
patients.
2. Results
Among the 189 starting candidate genes selected, 120 did not reveal
any SNP in their 3′ UTRs while 58 genes did not reveal SNPs in miRNA
target sequences. In silico analysis of the dbEST database and dbSNP
database provided us with potential candidates for miRNA-binding
SNPs. The remaining 10 genes showed SNPs in the predicted miRNA-
binding sites and ﬂanking regions and were further investigated in the
case-control study (Table 1). We further analyzed allele frequency of
SNPs that are located within 200 nucleotide of the predicted miRNA
target pairs, by extracting two sets of sequences, onewith thewild type
allele and other with the polymorphic allele at the same nucleotide
position of this stretch. Then, we computationally determined the
secondary structures using RNAFold program for both the sequences
[16] and RNA hybrid plot the binding patterns of BCL2—miR195 binding
in different allelic stage (Fig. 1). Further, we compared the allele
frequency of each SNP found in cancer tissues with that found in the
dbSNP database and in the control samples. Of the 51 cervical cancer
patients genotyped for HPV status, 37 patients were seen to be positive
for HPV 16 and 14 patients were positive for HPV 18. Ten SNPs from
different genes were tested and it was observed that rs4987856
polymorphism in BCL2 is a potential target gene of miR-195 and had a
signiﬁcantly aberrant SNP allele in cancer tissues as comparedwith that
of the control population (Fig. 2).
Table 2 shows statistical analysis, for the selected SNPs in themiRNA
target sequences. TheC toT (rs4987856) change ingenotypeof theBCL2
polymorphism was observed in 82.4% of the cancer patients and less
than 9.4% of the control population (Table 2) (Fig. 2). We found that
none of the other 9 SNPs (AKT1_ rs968554, MAP3K11_ rs72631835,
ALOX15_ rs916055, NF-kB_ rs4648143, TP53_ rs2543552, VEG-
FA_rs6122014, MYC_rs58463981, NOTCH1_rs59342860 and BCL2_
rs3744935) had a signiﬁcant difference of allele frequency in the normal
subjects from that in the cancer population.
Age greater than or equal to 50 group showed a 9-fold increase in
risk of cervical cancer (95% CI: 3.8 to 23.3). Owing to less number of
homozygous polymorphic individuals, both homozygous and hetero-Table 1
List of genes with polymorphic miRNA target sites with allelic variation.
Target gene miRNA SNPs Alleles
TP53 hsa-miR-150 rs2543552 A/G
NOTCH1 hsa-miR-200c rs59342860 G/T
MAP3K11 hsa-miR-199b-5p rs72631835 G/A
NF-kB hsa-miR-557 rs4648143 A/G
ALOX15 hsa-miR-588 rs916055 C/T
AKT1 hsa-miR-143 rs968554 C/G
VEGFA hsa-miR-1 rs6122014 G/A
MYC hsa-miR-200c rs58463981 C/T
BCL2 hsa-miR-195 rs4987856 C/T
BCL2 hsa-miR-619 rs3744935 C/Tzygous conditions were combined together for statistical analysis. The
presence of variant allele (C/T) of BCL2 gene at the target site of miR-
195 was associated with an increased risk of cervical cancer (Adjusted
OR=54.4, 95% CI: 13.1 to 226.1). Polymorphism in the MYC and
VEGFA genes did not showing any signiﬁcant risk when adjusted for
age group.
3. Discussion
To investigate the inﬂuence of putative functional polymorphisms in
microRNA binding sites located in cancer relevant genes on cervical
cancer risk, we ﬁrst performed an in silico study to validate miRNA and
their targets in cervical cancer and to search out SNPs in seed region of
these target genes and associated aberrant alleles conﬁrmed through
genotyping. Interestingly, BCL2was the only target genewhich showed
SNP in seed region and this was conﬁrmed by the case-control analysis.
We compared our results with ﬁndings from genome-wide studies, for
which we checked if these SNPs have been analyzed in the Cancer
Genetic Markers of Susceptibility (CGEM) genome-wide association
study (CGEMS) (https://caintegrator.nci.nih.gov/cgems/browseSetup.
do).The variant allele BCL2_ rs4987856 located in the miRNA-binding
site in the 3′UTR of the BCL2 indicated an associationwith cancer risk in
an allele dose-dependent manner.
BCL2 is a member of the apoptotic signaling in response to DNA
damage, a group of transcription factors which activates gene
expression by recruiting multiple co-activators [17] and [18]. MiR-195
is predicted to bind a large number of target mRNAs and BCL2 is one
Fig. 2. Representative sequencing results of cervical tumor samples validating the
aberrant allele frequency of SNP rs4987856. A cervical tumor sample displays an allelic
change C to T. Arrow indicates the SNP position.
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affects the miRNA-binding site of miR-195.The difference in free
energies between the two alleles was above the cut off value assigned
in methods (dG=−30.87 and dG=−24.8) (Fig. 1). In silico analysis
using different target prediction tools (see materials and methods)
showed that the variant BCL2_ rs3744935 does not signiﬁcantly affect
(below the cut off value assigned) the binding capacity of miR-619.
In our case-control study the rs4987856 polymorphism of BCL2 was
found associated with an increased risk of cervical cancer. BCL2_
rs4987856 affects the binding capacity of miR-195, which is stronger
when the C-allele is present. In contrast, when C is substituted by T-Table 2
Logistic regression analysis for the selected SNPs in the miRNA target sequences.
Controls Cases Odds ratios 95% C
N (%) N (%)
Total number 53 51
Age group
b50 43 (81.1) 16 (31.4) 1
≥50 10 (18.9) 35 (68.6) 9.4 3.8–
BCL2
CC 48 (90.6) 9 (17.7) 1
CT+TT 5 (9.43) 42 (82.4) 44.8 13.9–
MYC
CC 48 (90.6) 38 (74.5) 1
CT+TT 5 (9.43) 13 (25.5) 3.3 1.1–
VEGFA
GG 46 (86.8) 42 (82.4) 1
GA+AA 7 (13.2) 9 (17.7) 1.4 0.5–
a Odds ratios adjusted for age group.allele it is predicted that the binding of miR-195 is weakened, which
might lead to a reducedmiRNA-mediated BCL2 repression, consequent-
ly leading to increased BCL2 protein levels and a higher risk of cervical
cancer [19,20] and [21]. About a decade back, our laboratory established
that relative levels of expression and interactions of p53, HPV-16/18 E6,
and bcl-2 plays a role in the development of cervical carcinogenesis [22].
However, here, for the ﬁrst time we ascertain that the molecular basis
for over expression of BCL2 in cervical cancer could be due to
polymorphism induced miRNA regulation. We understand that these
results needs to be validated in larger population studies, but the fact
that the present results from this in- silico ﬁnding, validated by our wet
lab studies and supported by our laboratory's previously established
results on BCL2 further stresses the importance of this protein in HPV
integrated cervical cancer. These facts togetherwith the established role
of miRNA regulation and BCL2 over expression with previous reports
may improve our understanding of cervical cancer progression [18,20]
and [21]. The protective effect observed for the C-allele is biologically
reasonable. However, further functional studies are necessary to test
this hypothesis. Since endogenous BCL2 levels are high in HPV positive
cases, it is possible that the risk effect of this variant can only bedetected
in HPV integrated cases.
To summarize BCL2_ rs4987856 is a functional candidate SNP in a
miRNA target site in a gene with a strong a priori biological relevance
and probability to be involved in cervical carcinogenesis. Inhibitory
effect of the C-allele which is associated in silico with a stronger
binding of miR-195 and the allele-dose dependency of this effect,
argues against a chance ﬁnding. However, large studies on large
sample sets will be needed to verify the association and to answer
questions regarding the possible impact of this variant on therapeutic
and clinical outcome.
4. Methods
4.1. Bioinformatics analysis
4.1.1. Selection of candidate genes
We focused ongenes regulating the cell cycle and tumor suppressing
activity and selected the most studied genes within this category,
according to information from a literature survey using (http://www.
ncbi.nlm.nih.gov/pubmed), BioCarta (http://cgap.nci.nih.gov/
Pathways/PathwayGenes), OMIM and KEGG pathways (http://www.
genome.jp/kegg). A total of 250 genes identiﬁed to have an etiological
associationwith cervical cancer are shown in supplementaryﬁle. For the
250 selected target genes identiﬁed fromby various tools,weperformed
the functional enrichment analysis using David Bioinformatics tool
(http://david.abcc.ncifcrf.gov/home.jsp). Of the 250 genes, David tool
selected 189 target genes as “Current Gene List” and the human whole
genome genes as “Current Background”. We then performed functionI p value Adjusted ORa 95% CI p value
23.3 b0.001
1
144 b0.001 54.4 13.1–226.1 b0.001
1
10 0.037 2.2 0.6–7.9 0.21
1
4.1 0.532 1.6 0.5–5.3 0.485
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The list include those genes with roles in disrupting the normal
biological processes such as apoptosis, DNA repair, the cell cycle
checkpoints and chemokine signaling pathways.4.1.2. MicroRNA-target site prediction
Mtar [23] searches Putative miRNA-binding sites of the 3’ UTRs
(http://utrdb.ba.itb.cnr.it/getutr) for segments of perfect Watson–Crick
complementarity to bases 2–8 of the miRNA numbered from the 5′ end
and compared with TargetScan, DIANA-MicroT, miRanda [24–26] and
[27]. To reduce the false positive rate of target prediction results we
compared with different algorithms. From the possible putative sites
only those miRNA target pairs had context score of 0.10 or above were
selected which were predicted to bind to the same target site by all the
four software. UTRdb is a curated database of 5′ and 3′ un-translated
sequences of eukaryotic mRNAs, derived from several sources of
primary data. Experimentally validated functional motifs are annotated
(and also collected as the UTRsite database) and cross-links to genomic
and protein data are provided. The details of the target binding miR
sequence and the chromosomal location were collected from the miR-
base (http://microrna.sanger.ac.uk).4.1.3. Sequence retrieval and SNP screening
Based on the results obtained from target prediction tools, we
retrieved the genome sequence (speciﬁcally 3′ UTR) of each gene were
obtained fromUCSCGenomebrowser (http://genome.ucsc.edu/cgi-bin/
hgGateway?org=Human&db) for our computational analysis. To
identify the SNPs that may contribute to cancer susceptibility, we
carried out a genome-wide scale in silico analysis using UCSC Genome
browser—dbSNP build 130 (http://genome.ucsc.edu/cgi-bin/hgc). The
SNPs residing on the miRNAbinding sites were screened by a
widespread search in dbSNP (http://www.ncbi.nlm.nih.gov/projects/
SNP), using BLAST (http://www.ncbi.nlm.-nih.gov/BLAST/Blast.cgi) and
BLAST-SNP algorithms (http://www.ncbi.nlm.nih.gov/SNP/
snpblastByChr.html).The SNPs located in the 3′ UTRs of selected genes
were identiﬁed using the chromosomal location information provided
in the dbSNP andUCSC genomebrowser. Functional signiﬁcance of each
SNP in un-translated region (UTR) was determined by UTRscan
available at (http://www.ba.itb.cnr.itt/BIG/UTRScan) [28]. Among the
polymorphisms in predicted miRNA-binding sites, we selected 10 SNPs
located in genes involved in cervical cancer to investigate their impact
on same. Table 1shows respective gene, the SNP and themiRNA, whose
target sequence is putatively affected, as well as the function of the
respective gene.4.1.4. Secondary structure prediction and binding energy determination
Free energy (ΔG) which determines the target accessibility of the
miRNA were found using mfold (Version 3.2) (http://mfold.bioinfo.
rpi.edu/). The mfold programminimizes a free energy function, which
sums contributions from stacking, loop lengths, etc. ΔG of the
reference sequence and that of the sequence that we generated
with the variant allele was found using RNAhybrid 2.2 (http://
bibiserv.techfak.uni-bielefeld.de/rnahybrid). RNAhybrid determines
the most favorable hybridization site between two sequences. The
binding energy requirement of the reference sequence and that of the
sequence with variant allele was designated as ΔG and ΔG′. The
difference of the free energies between the two alleles is deﬁned as
ΔΔGtot. The difference in the ΔG's would be an indication of whether
the occurrence of SNP could impact the interaction of that particular
miRNA with its Target site. According to Landi et al. SNP had a ΔΔG tot
value greater than −5.27 kJ/mol was considered biologically relevant,
whereas SNPs with ΔΔG tot value less than −5.27 kJ/mol were
consideredbiologically neutral andnot included in further analyses [10].4.2. Experimental analysis
4.2.1. Study subjects
Tissue biopsies were collected from 51 patients with cervical
carcinoma attending the Gynecological Oncology Clinic of the Regional
Cancer Centre, Thiruvananthapuram. As normal controls, 53 apparently
normal subjects without any history of malignancy or systemic disease
were also included. The studywas approved by the Institutional Review
Board and Human Ethics Committee of the Regional Cancer Centre.
Informed consent was obtained from all subjects.
4.2.2. Cell lines
Human cervical cancer cell lines C33A,HeLa and SiHa (obtained from
National Centre for Cell Science, Pune, India) were grown in DMEM
(Sigma) supplementedwith 10% FBS 100 U/ml penicillin and 100 μg/ml
streptomycin (Invitrogen Life Technologies, Carlsbad, CA, USA).
4.2.3. HPV determination and SNP genotyping
Genomic DNAs were extracted using ALL Prep DNA/RNA mini Kit
(Qiagen) following the manufacturer's protocol. PCR ampliﬁcation of
HPV consensus primers were carried out on the extracted DNA as
described earlier [29]. All the PCR reactions were performed in a total
reaction volume of 50 μl containing 100 ng of genomic DNA, 0.4 mM
dNTPs, 5 pmol of each primer, 1.25 unit of Taq DNA polymerase and 1×
PCR buffer, [50 mM KCl, 10 mM Tris–HCl (pH 9.0), 1.5 mM MgCl2 and
0.1% Triton X-100]. Thermal cycling conditions were as follows: initial
denaturation at 94 °C for 5 min, 35 cycles of 40 s at 94 °C, 30 s at 55 °C
and 40 s at 72 °C, subsequently followed by a ﬁnal 10 min extension
period at 72 °C for 5 min. Gel elutions were done using GFX PCR DNA
and a gel band puriﬁcation kit (GEHealthcare, USA). Sampleswere then
sequenced in the ABI Prism 7900HT detection system (Applied
Biosystems) and data analysed using the BioEdit software version
7.0.5 (http://www.mbio.ncsu.edu/BioEdit/bioedit.html).
4.2.4. Statistical analysis
Statistical analysis was done using the STATA software version 8.0
(Stata Corp. LP, College Station, TX).Risk of cervical cancer was
analyzed using Chi square (v2) test. The association between poly-
morphisms and cervical cancer risk was analyzed by calculating the
crude odds ratios (OR) and 95% conﬁdence intervals (95% CI) using
the chi-square-test. The odds ratio adjusted for age, sex and habits
were calculated using unconditional logistic regression analysis with
the low risk genotype designated as the referent category. The p
values reported in the study are based on two-sided probability test
with a signiﬁcance level of pb0.05.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.ygeno.2011.06.005.
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